247 related articles for article (PubMed ID: 21174067)
1. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
2. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
3. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
8. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II).
Fujita E; Kouroku Y; Isoai A; Kumagai H; Misutani A; Matsuda C; Hayashi YK; Momoi T
Hum Mol Genet; 2007 Mar; 16(6):618-29. PubMed ID: 17331981
[TBL] [Abstract][Full Text] [Related]
9. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
[TBL] [Abstract][Full Text] [Related]
10. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
13. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
14. Regulation of autophagy by ATF4 in response to severe hypoxia.
Rzymski T; Milani M; Pike L; Buffa F; Mellor HR; Winchester L; Pires I; Hammond E; Ragoussis I; Harris AL
Oncogene; 2010 Aug; 29(31):4424-35. PubMed ID: 20514020
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells.
Kawakami T; Inagi R; Takano H; Sato S; Ingelfinger JR; Fujita T; Nangaku M
Nephrol Dial Transplant; 2009 Sep; 24(9):2665-72. PubMed ID: 19454529
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
17. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
18. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
